Ratutrelvir (83-0060)

Phase 2Small molecule

TTraws Pharma, Inc.

Ratutrelvir (83-0060) is one of 19 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

Activella

Eli Lilly

Preclinical

—3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

SARS-COV-2 VACCINE

Moderna

Preclinical

2 6

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 8

Ratutrelvir (83-0060)

TTraws Pharma, Inc.

Phase 2

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Recruiting·TTraws Pharma, Inc.·Phase 2·NCT07157007·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ratutrelvir (83-0060). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ratutrelvir (83-0060) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ratutrelvir (83-0060). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Traws Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTraws Pharma, Inc.

Ratutrelvir (83-0060)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

References

Drug Info

Quick Facts

Related News